Related Experiment Video
Updated: Aug 8, 2026

Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds
Published on: October 29, 2015
Established and emerging therapies for the treatment of viral hepatitis
Daniel Forton1, Peter Karayiannis
1Department of Medicine A, Imperial College, St Mary's Campus, London, UK.
Abstract:
Patients who are chronically infected with either hepatitis B or C viruses run the risk of developing cirrhosis and hepatocellular carcinoma in later life. Antiviral treatment offers the only means of interrupting this progression. To date, recombinant interferon alpha and the nucleos(t)ide analogues lamivudine and adefovir dipivoxil are the only licensed drugs for the treatment of chronic hepatitis B, whilst recombinant or pegylated interferons in combination with ribavirin are the ones used for chronic hepatitis C virus infections. The efficacy of these treatments, reasons for treatment failure, drug resistance and future options are discussed in the present review.
Related Concept Videos
Hepatitis
Inhibitors of Viral Protein Synthesis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Microorganisms in Medicine and Therapeutics
Retrovirus Life Cycles
